The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Subscribe To Our Newsletter & Stay Updated
